Prot# FavId-04: Phase II Trial of Rituxan® plus FavId? (Tumor-Specific Idiotype-KLH) and GM-CSF Immunotherapy in Patients with Grade 1 or 2 Follicular B-Cell Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date2/25/031/1/11

Funding

  • Favrille, Inc. (FavId-04)